Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92,588 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors.
Huang Z, Xu Y, Hong W, Gong L, Chen K, Qin J, Xie F, Wang F, Tian X, Meng X, Feng W, Li L, Zhang B, Kang X, Fan Y. Huang Z, et al. Among authors: li l. Front Immunol. 2023 Oct 23;14:1258573. doi: 10.3389/fimmu.2023.1258573. eCollection 2023. Front Immunol. 2023. PMID: 37936687 Free PMC article. Clinical Trial.
Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE).
Shi Y, Chen J, Yang R, Wu H, Wang Z, Yang W, Cui J, Zhang Y, Liu C, Cheng Y, Liu Y, Shan J, Wang D, Yang L, Hu C, Zhao J, Cao R, Tan B, Xu K, Si M, Li H, Mao R, Li L, Kang X, Wang L. Shi Y, et al. Among authors: li h, li l. J Thorac Oncol. 2024 Jan 25:S1556-0864(24)00033-9. doi: 10.1016/j.jtho.2024.01.013. Online ahead of print. J Thorac Oncol. 2024. PMID: 38280448 Free article.
QL1604 plus paclitaxel-cisplatin/carboplatin in patients with recurrent or metastatic cervical cancer: an open-label, single-arm, phase II trial.
Fang C, Zhou Y, Feng Y, He L, Yu J, Li Y, Feng M, Pan M, Zhao L, Tang D, Li X, Tan B, An R, Zheng X, Si M, Zhang B, Li L, Kang X, Zhou Q, Liu J. Fang C, et al. Among authors: li y, li x, li l. J Gynecol Oncol. 2024 Mar 29. doi: 10.3802/jgo.2024.35.e77. Online ahead of print. J Gynecol Oncol. 2024. PMID: 38606822 Free article.
Interventions to Prevent Falls in Community-Dwelling Older Adults: US Preventive Services Task Force Recommendation Statement.
US Preventive Services Task Force; Nicholson WK, Silverstein M, Wong JB, Barry MJ, Chelmow D, Coker TR, Davis EM, Jaén CR, Krousel-Wood M, Lee S, Li L, Rao G, Ruiz JM, Stevermer J, Tsevat J, Underwood SM, Wiehe S. US Preventive Services Task Force, et al. Among authors: li l. JAMA. 2024 Jun 4. doi: 10.1001/jama.2024.8481. Online ahead of print. JAMA. 2024. PMID: 38833246
Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations.
Shen M, Chen S, Han X, Hao Y, Wang J, Li L, Chen T, Wang B, Zou L, Zhang T, Zhang W, Han X, Wang W, Yu H, Li K, Liu S, Jin A. Shen M, et al. Among authors: li l. Cancer Immunol Immunother. 2024 Jun 4;73(8):150. doi: 10.1007/s00262-024-03729-y. Cancer Immunol Immunother. 2024. PMID: 38832948
92,588 results
You have reached the last available page of results. Please see the User Guide for more information.